600566 Hubei Jumpcan Pharmaceutical
- 38.09
- +0.01+0.03%
Hubei Jumpcan Pharmaceutical News
Is Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Recent Stock Performance Tethered To Its Strong Fundamentals?
Hubei Jumpcan Pharmaceutical's (SHSE:600566) stock is up by a considerable 11% over the past three months. Since the market usually pay for a company's long-term fundamentals, we decided to study th
Jichuan Pharmaceutical (600566): Excellent 24Q1 performance, steady core product performance, and employee stock ownership plans show confidence
The incident company achieved operating income of 9.655 billion yuan in 2023, +7.32% year on year; net profit to mother of 2,823 billion yuan, +30.04% year on year; net profit after deducting non-return to mother of 2,692 billion yuan, +32 year on year.
Jichuan Pharmaceutical (600566.SH): A total of 961,700 shares have been repurchased
Gelonghui, May 6, 丨 Jichuan Pharmaceutical (600566.SH) announced that as of April 30, 2024, the company had repurchased a total of 961,700 shares through centralized bidding transactions, accounting for 0.10% of the company's total share capital. The highest purchase price was 30.97 yuan/share, the lowest price was 27.19 yuan/share, and the total amount paid was RMB 27,094,699.88 (not including transaction fees).
Jichuan Pharmaceutical (600566): Strong sales in core categories, 24Q1 profit growth exceeded expectations
Incident: The company recently released its 2023 annual report and the 2024 first quarter results report: achieved operating revenue of 9.655 billion yuan (+7.32%) in 2023, of which the main business revenue was 9.638 billion yuan (+7.37%)
Here's Why We Think Hubei Jumpcan Pharmaceutical (SHSE:600566) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Jichuan Pharmaceutical (600566): Outstanding sales of core categories, gradual increase in profitability
The scale of revenue has expanded steadily, and profits have grown rapidly, maintaining that the “buy” rating company achieved revenue of 9.655 billion yuan in 2023 (+7.32% year over year; the following are all year-on-year ratios); net profit to mother was 2,823 billion yuan (+3
Jichuan Pharmaceutical (600566): The 24Q1 profit growth rate exceeded expectations, and the employee stock ownership plan showed long-term business confidence
Incident: The company released its 2024 quarterly report. In Q1 of 2024, the company achieved revenue of 2,403 billion yuan, a year-on-year increase of 0.6%, and realized net profit of 845 million yuan, an increase of 24.90% over the previous year. Company 20
Zhongtai Securities released a research report on April 21 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) Q1 performance surpassed expectations, and the return home achieved 25% growt
Zhongtai Securities released a research report on April 21 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) Q1 performance surpassed expectations, and the return home achieved 25% growth; 2) cost-side optimization led to a significant increase in net interest rates. (Mainichi Keizai Shimbun)
Jichuan Pharmaceutical (600566): The profit growth rate continues to exceed expectations, and the sales platform has significant advantages
Incident: The company recently released the 2023 annual report and the 2024 first quarter report. In 2023, the company achieved revenue of 9.655 billion yuan, an increase of 7.32% over the previous year; net profit to mother was 2,823 billion yuan, the same
Open Source Securities released a research report on April 20 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the rotation and handover of growth drivers, and pediatrics has become the
Open Source Securities released a research report on April 20 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the rotation and handover of growth drivers, and pediatrics has become the mainstay; 2) optimizing the product structure, steady growth in basic markets, and accelerating the release of advantageous individual products; 3) increasing the introduction and R&D of new products, deepening sales advantages and enabling sustainable development. (Mainichi Keizai Shimbun)
Jichuan Pharmaceutical (600566): Fee control guarantees high profit growth and improved operating capacity
Guide to this report: The company released its 2024 quarterly report. Revenue grew steadily, profit slightly exceeded expectations, benefiting from continued improvement in fee control capacity, continued high profit growth, and improved operating capacity. It is expected that subsequent performance will continue to grow. throws
Jichuan Pharmaceutical (600566) Company's First Coverage Report: Pediatric Business Accelerates Sailing, High Quality BD Empowers Long-term Development
Growth momentum has been rotated and handed over. Pediatrics has become a mainstay. Jecheon Pharmaceutical was founded in 1994 and launched in 2013, focusing on the production and sale of pediatric, oral, respiratory, digestive, obstetrics and gynecology, and other fields. The company's current products
Jichuan Pharmaceutical (600566.SH): Net profit of 845 million yuan in the first quarter increased 24.90% year-on-year
Gelonghui, April 19: Jichuan Pharmaceutical (600566.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 2,403 billion yuan, an increase of 0.60%; net profit attributable to shareholders of listed companies of 845 million yuan, an increase of 24.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 726 million yuan, an increase of 19.83% year on year; basic earnings per share were 0.923 yuan.
Jichuan Pharmaceutical (600566): Performance exceeds expectations, profitability improved significantly
Key investment events: Jichuan Pharmaceutical released its 2024 quarterly report. During the reporting period, it achieved revenue of 2,403 billion yuan (+0.60% YoY) and net profit of 845 million yuan (YoY +24.90%), net profit not attributable to mother
Dongwu Securities released a research report on April 17 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the accelerated release of Q4 profits, which are expected to maintain high prof
Dongwu Securities released a research report on April 17 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the accelerated release of Q4 profits, which are expected to maintain high profit margins in 2024; 2) the cost ratio is well controlled to accelerate the release of profits; 3) the release of a new round of equity incentive plans. (Mainichi Keizai Shimbun)
Jichuan Pharmaceutical (600566): Expenses were effectively controlled during the period, and profit margins were further increased
Incident: The company released its 2023 annual report, achieving operating income of 9.655 billion yuan (+7.32%), net profit to mother of 2,823 billion yuan (+30.04%), and net profit of non-return to mother of 2,692 billion yuan (+3)
Jichuan Pharmaceutical (600566) 2023 Annual Report Review Report: Rapid growth in performance, steady progress in BD innovation and transformation
Incident: On April 10, 2024, Jichuan Pharmaceutical issued an announcement: In 2023, the company achieved operating income of 9.655 billion yuan, an increase of 7.32% over the previous year; net profit to mother was 2,823 billion yuan, an increase of 30.0 billion yuan over the previous year
Southwest Securities released a research report on April 11 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the profit growth rate in 2023 exceeded expectations, and profitability was
Southwest Securities released a research report on April 11 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the profit growth rate in 2023 exceeded expectations, and profitability was further improved; 2) “cinema+retail” diversified channel efforts to deepen the construction of an academic platform; 3) the steady progress of BD to create a new engine for growth. (Mainichi Keizai Shimbun)
Jichuan Pharmaceutical (600566) 2023 Annual Report Review: Cost Control Shows Results, Performance Growth Exceeds Expectations
Incident: Jichuan Pharmaceutical released its 2023 annual report. During the reporting period, the company achieved operating income of 9.655 billion yuan (+7.32% year over year); net profit attributable to mother of 2,823 billion yuan (+30.04% year over year); net profit not attributable to mother
Jichuan Pharmaceutical (600566): Performance growth exceeds expectations, BD projects are expected to contribute new impetus
Incident: In 2023, the company achieved operating income of 9.655 billion yuan, an increase of 7.32% over the previous year; net profit attributable to the owners of the parent company was 2,823 billion yuan, an increase of 30.04% over the previous year
Analysis
Price Target
No Data
